Stuart Seropian

Dr. Stuart Seropian is Professor of Internal Medicine (Hematology) at Yale School of Medicine and holds multiple leadership positions at Yale Cancer Center and Smilow Cancer Hospital. He currently serves as Acting Director of the Stem Cell Transplantation Program, Chairman of the Car-T Cell Joint Steering Committee, Director of the Unrelated Donor Transplant Program, and Co-Director of both the Immune Effector Cell Therapy Program and the Adult CAR T-Cell Therapy Program.

Dr. Seropian received his medical degree from George Washington University School of Medicine in 1991, where he graduated with distinction and was honored with the Horowitz Award for NBME Part I. He completed his residency and fellowship training at Yale-New Haven Hospital/Yale University School of Medicine in 1996, and has remained at Yale as faculty, rising to his current professorship.

His research focuses on hematopoietic stem cell transplantation, CAR T-cell therapy, and treatment of hematologic malignancies including acute myeloid leukemia (AML) and lymphomas. Recent publications show significant involvement in the SIERRA trial evaluating 131I-Apamistamab for AML treatment and research on T-cell fitness markers for predicting immunotherapy response. His work particularly emphasizes improving transplantation outcomes through novel anti-cancer agents and methods to treat graft-versus-host disease.

Dr. Seropian has received multiple honors including:

• Yale Cancer Center Award for Clinical Excellence (2016)
• David S. Fischer Annual Award for Outstanding Teaching and Mentoring of Fellows in Hematology (2014)
• Alpha Omega Alpha Medical Honor Society (1991)
• MD with Distinction, George Washington University School of Medicine (1991)
• Horowitz Award, NBME Part I (1989)

As a clinician, Dr. Seropian specializes in treating patients with blood cancers including acute and chronic leukemia, non-Hodgkin's lymphoma, and multiple myeloma, as well as non-cancerous bone marrow disorders such as aplastic anemia. He emphasizes long-term patient relationships and a team-based approach to care, stating that 'patients who come here are cared for by a family of people.'

Dr. Seropian serves as a sub-investigator on multiple clinical trials investigating novel treatments for lymphoma and myeloma, with a particular focus on cellular therapies. His leadership roles position him at the forefront of advancing stem cell transplantation and CAR T-cell therapy at Yale.